Halozyme Enters Global Exclusive Collaboration with Oruka
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme's wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. Oruka has licensed Halozyme's Hypercon technology for use with ORKA-001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, reducing injection volume for a given dose and supporting more convenient, patient-friendly administration. Under the terms of the agreement, Oruka will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be eligible to receive mid-single digit royalties on net sales of products developed using the Hypercon technology.
